Fischl et al. (2019) recently reported that S1P1 antagonism is sufficient to enhance the efficacy of the VEGFR inhibitor sunitinib in vitro and in vivo in the postnatal retinal angiogenesis model and in the RCC murine tumor model [39]. The gene discussed is S1PR1; the disease is renal cell carcinoma.